Aptose Biosciences (NASDAQ:APTO) Stock Rating Reaffirmed by HC WainwrightTicker Report • 19 days ago
HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO - Free Report) (TSE:APS) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright...
Share to Feed
Aptose Biosciences (NASDAQ:APTO - Get Free Report) (TSE:APS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on...
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 50,200...
Shares of Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) have earned an average rating of Buy from the five research firms that are currently covering the...
Related Stocks: NAS:APTO...
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired...
Aptose Biosciences Q4 2023 Earnings Preview...
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) has earned a consensus rating of Buy from the six brokerages that are presently covering the stock, MarketBeat...
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral...